AMZN enters the week after its Q2 earnings gap still holding the bulk of those gains — but Tuesday's 2.3% pullback to $277.42 marks the first real test of whether the 20% weekly surge can find support at these levels.
The Q2 print delivered a 19.8% single-day jump, the mechanics of which were documented in Sunday's stock report. What has changed since then is the post-gap consolidation picture. The stock is up 20% on the week and 14% over the past month — a pace that has now brought it within striking distance of the Street's consensus target of $325. That gap, which looked wide at $230 last week, has compressed to roughly 17%. The question the next few weeks need to answer is whether the repricing stalls here or whether the earnings revision cycle has enough momentum to carry it further.
The analyst community answered the Q2 print with near-universal target raises. A wave of firms lifted numbers on July 31, all maintaining positive ratings: UBS to $318, Bernstein and Mizuho both to $330, RBC Capital to $330, Citigroup and TD Cowen both to $350, Wells Fargo to $328. The one outlier was DA Davidson, which held its Neutral rating and $250 target unchanged — the only voice on the Street currently below the current price. The consensus is constructive, with factor scores backing the tone: EPS momentum over the past 30 days ranks in the 93rd percentile, EPS surprise in the 91st. The forward earnings yield picture is less compelling — the EPS 12-month forward year-on-year growth factor scores in the 7th percentile — which is where the bear case lives. The P/E has pulled back roughly 1.2 turns over the past month to 24.9x, and EV/EBITDA has eased 0.65 turns to 11.97x. Neither is stretched, but neither offers obvious value at $277 after a 20% week.
Positioning tells a quiet story throughout. Options are essentially neutral: the put/call ratio is 0.70, sitting almost exactly on its 20-day average and carrying a z-score near zero. That is a marked contrast to the defensive 0.75 PCR documented ahead of the Q2 print. The borrow market remains what it has been for months — entirely frictionless. Availability is at ORTEX's maximum display level, cost to borrow is just 0.27%, and short interest is 1.0% of the free float after edging up roughly 0.5% on the week. None of those numbers represent friction or pressure. The ORTEX short score is 29.4, drifting slightly lower over the past two weeks, consistent with a stock where short-side pressure is not a factor.
Peer performance has shifted character from the post-print week. The prior stock report documented a sharp divergence — Amazon up 17% while MELI, CPNG, and JMIA fell between 10% and 16%. This week, correlations are partly reasserting. BABA rose 12% on the week. CPNG added 8.7%. MELI was roughly flat at +1.4%. EBAY bucked the trend, falling 6.7%. The category is no longer uniformly moving against Amazon — which removes one of the cleaner narratives from last week, and makes the stock's next move more dependent on its own data rather than relative divergence.
The next scheduled catalyst is Q3 earnings on October 30. Between now and then, the watch is straightforward: whether the analyst revision cycle — which has carried consensus targets from the low $300s into the high $320s to $350 range — continues to close the remaining gap to where the stock now trades, or whether the compression of that gap starts to reduce the magnetic pull that drove institutional buying into the Q2 print.
See the live data behind this article on ORTEX.
Open AMZN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
